Autoimmune and infectious skin diseases that target desmogleins.
Desmosomes are intercellular adhesive junctions of epithelial cells that contain two major transmembrane components, the desmogleins (Dsg) and desmocollins (Dsc), which are cadherin-type cell-cell adhesion molecules and are anchored to intermediate filaments of keratin through interactions with plakoglobin and desmoplakin. Desmosomes play an important role in maintaining the proper structure and barrier function of the epidermis and mucous epithelia. Four Dsg isoforms have been identified to date, Dsg1-Dsg4, and are involved in several skin and heart diseases. Dsg1 and Dsg3 are the two major Dsg isoforms in the skin and mucous membranes, and are targeted by IgG autoantibodies in pemphigus, an autoimmune disease of the skin and mucous membranes. Dsg1 is also targeted by exfoliative toxin (ET) released by Staphylococcus aureus in the infectious skin diseases bullous impetigo and staphylococcal scalded skin syndrome (SSSS). ET is a unique serine protease that shows lock and key specificity to Dsg1. Dsg2 is expressed in all tissues possessing desmosomes, including simple epithelia and myocardia, and mutations in this gene are responsible for arrhythmogenic right ventricular cardiomyopathy/dysplasia. Dsg4 plays an important adhesive role mainly in hair follicles, and Dsg4 mutations cause abnormal hair development. Recently, an active disease model for pemphigus was generated by a unique approach using autoantigen-deficient mice that do not acquire tolerance against the defective autoantigen. Adoptive transfer of Dsg3(-/-) lymphocytes into mice expressing Dsg3 induces stable anti-Dsg3 IgG production with development of the pemphigus phenotype. This mouse model is a valuable tool with which to investigate immunological mechanisms of harmful IgG autoantibody production in pemphigus. Further investigation of desmoglein molecules will continue to provide insight into the unsolved pathophysiological mechanisms of diseases and aid in the development of novel therapeutic strategies with minimal side effects.
Amagai
Masayuki
M
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. amagai@sc.itc.keio.ac.jp
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology*; D051182:Desmogleins / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D020033:Protein Isoforms / Q000276:immunology; D012874:Skin Diseases, Infectious / Q000175:diagnosis / Q000276:immunology*
D001323:Autoantibodies; D051182:Desmogleins; D007074:Immunoglobulin G; D020033:Protein Isoforms
J Immunol. 1997 Aug 15;159(4):2010-7
9257868
J Clin Invest. 2004 Nov;114(10):1484-92
15545999
N Engl J Med. 1982 May 20;306(20):1189-96
7040962
N Engl J Med. 1990 Dec 20;323(25):1729-35
2247105
Br J Dermatol. 2002 Aug;147(2):261-5
12174096
J Clin Invest. 1992 Sep;90(3):919-26
1522242
Exp Cell Res. 1994 Apr;211(2):391-9
8143788
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2264-71
8637861
Am J Hum Genet. 2006 Jul;79(1):136-42
16773573
J Invest Dermatol. 1995 Jan;104(1):27-32
7528244
Circulation. 2006 Mar 7;113(9):1171-9
16505173
Exp Dermatol. 2009 Mar;18(3):252-60
18643850
Science. 1989 Nov 24;246(4933):982
2686027
J Invest Dermatol. 2006 Sep;126(9):2139-41
16691200
J Invest Dermatol. 2008 Apr;128(4):939-48
18007588
J Invest Dermatol. 1995 Jan;104(1):146-52
7798634
Biochemistry. 1999 Aug 10;38(32):10239-46
10441117
Br J Dermatol. 1999 Feb;140(2):351-7
10233237
Adv Dermatol. 1997;12:77-96; discussion 97
8973736
JAMA. 1992 Mar 18;267(11):1500-2
1538540
J Immunol. 2009 Feb 1;182(3):1740-5
19155523
J Immunol. 2003 Feb 15;170(4):2170-8
12574390
J Clin Invest. 2005 Apr;115(4):888-99
15841178
Nat Med. 2000 Nov;6(11):1275-7
11062541
Nature. 1995 Mar 23;374(6520):327-37
7885471
N Engl J Med. 1970 May 14;282(20):1114-9
4245327
Biochemistry. 1997 Feb 18;36(7):1559-66
9048539
J Clin Invest. 2000 Mar;105(5):625-31
10712434
Hum Mol Genet. 1999 Jun;8(6):971-6
10332028
Science. 1991 Mar 22;251(5000):1451-5
2006419
Structure. 1997 Jun 15;5(6):813-24
9261066
Eur J Immunol. 2002 Mar;32(3):627-33
11857336
Science. 2002 May 17;296(5571):1308-13
11964443
J Invest Dermatol. 1990 Mar;94(3):327-31
2307852
J Invest Dermatol. 1976 Aug;67(2):254-60
950490
N Engl J Med. 2006 Oct 26;355(17):1800-10
17065642
Cell. 2003 Apr 18;113(2):249-60
12705872
Cell. 1990 Apr 6;61(1):147-55
2317870
Infect Immun. 2002 Oct;70(10):5835-45
12228315
J Invest Dermatol. 1995 Jun;104(6):895-901
7539469
J Cell Biol. 1997 Jun 2;137(5):1091-102
9166409
J Immunol. 2008 Jul 15;181(2):1526-35
18606708
J Clin Invest. 1982 Aug;70(2):281-8
7047566
Proc Soc Exp Biol Med. 1964 Nov;117:505-10
14233481
Cell. 1991 Nov 29;67(5):869-77
1720352
Br J Dermatol. 1971 Jan;84(1):7-13
5573187
N Engl J Med. 1999 May 6;340(18):1406-10
10228191
Eur J Cell Biol. 1990 Oct;53(1):1-12
1706270
J Invest Dermatol. 2002 May;118(5):845-50
11982763
J Dermatol Sci. 1999 Jun;20(2):92-102
10379702
J Invest Dermatol. 2002 Jan;118(1):199-204
11851895
J Clin Invest. 1999 Feb;103(4):461-8
10021453
Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16
11252896
J Immunol. 2001 Nov 1;167(9):5439-48
11673563
J Clin Invest. 1994 Jul;94(1):59-67
8040292
Nature. 1987 Sep 24-30;329(6137):341-3
3498123